(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2011 (17.02.2011)

PCT

(10) International Publication Number
WO 2011/019798 A1

(51) **International Patent Classification**:
A61P 35/02 (2006.01) ***A61K 31/506*** (2006.01)
A61K 31/4433 (2006.01)

(21) **International Application Number**:
PCT/US2010/045133

(22) **International Filing Date**:
11 August 2010 (11.08.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
12/539,855 12 August 2009 (12.08.2009) US

(71) **Applicants** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW** [GB/GB]; University Avenue, Glasgow G12 8QQ (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **COPLAND, Mhairi** [GB/GB]; Paul O'gorman Leukemia Research Centre, University Of Glosgow, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 OYN (GB). **DORSCH, Marion** [DE/US]; Novartis Institutes Of Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **IRVINE, David** [GB/GB]; Paul O'gorman Leukemia Research Centre, University Of Glasgow, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 OYN (GB). **MANLEY, Paul, W.** [GB/CH]; Novarrtis Pharma Ag, Postfach, CH-4002 Basel (CH). **PEUKERT, Stefan** [DE/US]; Novartis Institutes Of Biomedical Research, Inc., Cambridge, MA 02139 (US).

(74) **Agent**: **MULKEEN, Matthew**; Novartis, Patent Department, One Health Plaza, Bldg. 101, East Hanover, NJ 07936-1080 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/019798 A1

(54) **Title**: METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA

(57) **Abstract**: A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.